Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms

B. Ferencz, K. Török, O. Pipek, J. Fillinger, K. Csende, A. Lantos, R. Černeková, M. Mitták, J. Škarda, P. Delongová, E. Megyesfalvi, K. Schelch, C. Lang, A. Solta, K. Boettiger, L. Brcic, J. Lindenmann, F. Rényi-Vámos, C. Aigner, J. Berta, Z....

. 2024 ; 73 (6) : 114. [pub] 20240502

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014011

Grantová podpora
TKP2021-EGA-33 Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
Semmelweis 250+ Excellence PhD Scholarship Semmelweis Egyetem
FWF No. T 1062-B33 Austrian Science Fund
FWF I3522 Austrian Science Fund
Innovative Interdisciplinary Cancer Research Hochschuljubiläumsstiftung der Stadt Wien
PC2022-II-19/1/2022 Magyar Tudományos Akadémia
Bolyai Research Scholarship Magyar Tudományos Akadémia
UNKP-20-3 Innovációs és Technológiai Minisztérium
International Lung Cancer Foundation Young Investigator Grant (2022) International Association for the Study of Lung Cancer

BACKGROUND: Advancements in immunotherapeutic approaches only had a modest impact on the therapy of lung neuroendocrine neoplasms (LNENs). Our multicenter study aimed to investigate the expression patterns of novel immunotherapy targets in intermediate- and high-grade LNENs. METHODS: The expressions of V-domain Ig suppressor of T cell activation (VISTA), OX40L, Glucocorticoid-induced TNF receptor (GITR), and T cell immunoglobulin and mucin domain 3 (TIM3) proteins were measured by immunohistochemistry in surgically resected tumor samples of 26 atypical carcinoid (AC), 49 large cell neuroendocrine lung cancer (LCNEC), and 66 small cell lung cancer (SCLC) patients. Tumor and immune cells were separately scored. RESULTS: Tumor cell TIM3 expression was the highest in ACs (p < 0.001), whereas elevated tumor cell GITR levels were characteristic for both ACs and SCLCs (p < 0.001 and p = 0.011, respectively). OX40L expression of tumor cells was considerably lower in ACs (vs. SCLCs; p < 0.001). Tumor cell VISTA expression was consistently low in LNENs, with no significant differences across histological subtypes. ACs were the least immunogenic tumors concerning immune cell abundance (p < 0.001). Immune cell VISTA and GITR expressions were also significantly lower in these intermediate-grade malignancies than in SCLCs or in LCNECs. Immune cell TIM3 and GITR expressions were associated with borderline prognostic significance in our multivariate model (p = 0.057 and p = 0.071, respectively). CONCLUSIONS: LNEN subtypes have characteristic and widely divergent VISTA, OX40L, GITR, and TIM3 protein expressions. By shedding light on the different expression patterns of these immunotherapy targets, the current multicenter study provides support for the future implementation of novel immunotherapeutic approaches.

Center for Cancer Research Medical University of Vienna Vienna Austria

Department of Clinical Pharmacology National Institute of Oncology Chest and Abdominal Tumors Chemotherapy B Budapest Hungary

Department of Pathology University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Physics of Complex Systems Eotvos Lorand University Budapest Hungary

Department of Pulmonary Diseases and Tuberculosis University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Thoracic Surgery Comprehensive Cancer Center Vienna Medical University of Vienna Waehringer Guertel 18 20 1090 Vienna Austria

Department of Thoracic Surgery Semmelweis University and National Institute of Oncology Budapest Hungary

Department of Translational Medicine Lund University Lund Sweden

Diagnostic and Research Institute of Pathology Medical University of Graz Graz Austria

Division of Pulmonology Department of Medicine 2 Medical University of Vienna Vienna Austria

Division of Thoracic and Hyperbaric Surgery Department of Surgery Medical University of Graz Graz Austria

Medical Faculty Institute of Clinical and Molecular Pathology Palacky University Olomouc Olomouc Czech Republic

National Institute of Oncology and National Tumor Biology Laboratory Budapest Hungary

National Koranyi Institute of Pulmonology Budapest Hungary

Surgical Clinic University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014011
003      
CZ-PrNML
005      
20240905133334.0
007      
ta
008      
240725s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00262-024-03704-7 $2 doi
035    __
$a (PubMed)38693435
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Ferencz, Bence $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary $u National Koranyi Institute of Pulmonology, Budapest, Hungary
245    10
$a Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms / $c B. Ferencz, K. Török, O. Pipek, J. Fillinger, K. Csende, A. Lantos, R. Černeková, M. Mitták, J. Škarda, P. Delongová, E. Megyesfalvi, K. Schelch, C. Lang, A. Solta, K. Boettiger, L. Brcic, J. Lindenmann, F. Rényi-Vámos, C. Aigner, J. Berta, Z. Megyesfalvi, B. Döme
520    9_
$a BACKGROUND: Advancements in immunotherapeutic approaches only had a modest impact on the therapy of lung neuroendocrine neoplasms (LNENs). Our multicenter study aimed to investigate the expression patterns of novel immunotherapy targets in intermediate- and high-grade LNENs. METHODS: The expressions of V-domain Ig suppressor of T cell activation (VISTA), OX40L, Glucocorticoid-induced TNF receptor (GITR), and T cell immunoglobulin and mucin domain 3 (TIM3) proteins were measured by immunohistochemistry in surgically resected tumor samples of 26 atypical carcinoid (AC), 49 large cell neuroendocrine lung cancer (LCNEC), and 66 small cell lung cancer (SCLC) patients. Tumor and immune cells were separately scored. RESULTS: Tumor cell TIM3 expression was the highest in ACs (p < 0.001), whereas elevated tumor cell GITR levels were characteristic for both ACs and SCLCs (p < 0.001 and p = 0.011, respectively). OX40L expression of tumor cells was considerably lower in ACs (vs. SCLCs; p < 0.001). Tumor cell VISTA expression was consistently low in LNENs, with no significant differences across histological subtypes. ACs were the least immunogenic tumors concerning immune cell abundance (p < 0.001). Immune cell VISTA and GITR expressions were also significantly lower in these intermediate-grade malignancies than in SCLCs or in LCNECs. Immune cell TIM3 and GITR expressions were associated with borderline prognostic significance in our multivariate model (p = 0.057 and p = 0.071, respectively). CONCLUSIONS: LNEN subtypes have characteristic and widely divergent VISTA, OX40L, GITR, and TIM3 protein expressions. By shedding light on the different expression patterns of these immunotherapy targets, the current multicenter study provides support for the future implementation of novel immunotherapeutic approaches.
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x imunologie $x patologie $x terapie $x metabolismus $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a buněčný receptor 2 viru hepatitidy A $x metabolismus $7 D000072597
650    12
$a imunoterapie $x metody $7 D007167
650    12
$a neuroendokrinní nádory $x imunologie $x metabolismus $x terapie $x patologie $7 D018358
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a glukokortikoidy indukovaný protein související s TNRF $x metabolismus $7 D053450
650    12
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a antigeny B7 $x metabolismus $7 D060887
650    _2
$a dospělí $7 D000328
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a ligand OX40 $x metabolismus $7 D053278
650    _2
$a prognóza $7 D011379
650    _2
$a senioři nad 80 let $7 D000369
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Török, Klára $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary $u National Koranyi Institute of Pulmonology, Budapest, Hungary
700    1_
$a Pipek, Orsolya $u Department of Physics of Complex Systems, Eotvos Lorand University, Budapest, Hungary
700    1_
$a Fillinger, János $u National Koranyi Institute of Pulmonology, Budapest, Hungary
700    1_
$a Csende, Kristóf $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary
700    1_
$a Lantos, András $u National Koranyi Institute of Pulmonology, Budapest, Hungary
700    1_
$a Černeková, Radoslava $u Department of Pulmonary Diseases and Tuberculosis, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Mitták, Marcel $u Surgical Clinic, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Škarda, Jozef $u Medical Faculty, Institute of Clinical and Molecular Pathology, Palacky University Olomouc, Olomouc, Czech Republic $u Department of Pathology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Delongová, Patricie $u Department of Pathology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Megyesfalvi, Evelyn $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary $u Department of Clinical Pharmacology, National Institute of Oncology, Chest and Abdominal Tumors Chemotherapy "B", Budapest, Hungary
700    1_
$a Schelch, Karin $u Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria $u Center for Cancer Research, Medical University of Vienna, Vienna, Austria
700    1_
$a Lang, Christian $u Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria $u Division of Pulmonology, Department of Medicine II, Medical University of Vienna, Vienna, Austria
700    1_
$a Solta, Anna $u Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
700    1_
$a Boettiger, Kristiina $u Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
700    1_
$a Brcic, Luka $u Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
700    1_
$a Lindenmann, Jörg $u Division of Thoracic and Hyperbaric Surgery, Department of Surgery, Medical University of Graz, Graz, Austria
700    1_
$a Rényi-Vámos, Ferenc $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary $u National Koranyi Institute of Pulmonology, Budapest, Hungary $u National Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary
700    1_
$a Aigner, Clemens $u Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
700    1_
$a Berta, Judit $u National Koranyi Institute of Pulmonology, Budapest, Hungary. berta.judit@koranyi.hu
700    1_
$a Megyesfalvi, Zsolt $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary $u National Koranyi Institute of Pulmonology, Budapest, Hungary $u Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
700    1_
$a Döme, Balázs $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary. balazs.dome@meduniwien.ac.at $u National Koranyi Institute of Pulmonology, Budapest, Hungary. balazs.dome@meduniwien.ac.at $u Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. balazs.dome@meduniwien.ac.at $u Department of Translational Medicine, Lund University, Lund, Sweden. balazs.dome@meduniwien.ac.at
773    0_
$w MED00001041 $t Cancer immunology and immunotherapy $x 1432-0851 $g Roč. 73, č. 6 (2024), s. 114
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38693435 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133328 $b ABA008
999    __
$a ok $b bmc $g 2143667 $s 1225877
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 73 $c 6 $d 114 $e 20240502 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
GRA    __
$a TKP2021-EGA-33 $p Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
GRA    __
$a Semmelweis 250+ Excellence PhD Scholarship $p Semmelweis Egyetem
GRA    __
$a FWF No. T 1062-B33 $p Austrian Science Fund
GRA    __
$a FWF I3522 $p Austrian Science Fund
GRA    __
$a Innovative Interdisciplinary Cancer Research $p Hochschuljubiläumsstiftung der Stadt Wien
GRA    __
$a PC2022-II-19/1/2022 $p Magyar Tudományos Akadémia
GRA    __
$a Bolyai Research Scholarship $p Magyar Tudományos Akadémia
GRA    __
$a UNKP-20-3 $p Innovációs és Technológiai Minisztérium
GRA    __
$a International Lung Cancer Foundation Young Investigator Grant (2022) $p International Association for the Study of Lung Cancer
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace